News Breaks |
|
|
| February 19, 2013 |
| 07:18 EDT |  | PFE, BMY, MRK | FBN Securities to host a tour
Healthcare Headquarter Tour travels throughout New York and New Jersey on February 19. |
|
|
News For PFE;MRK;BMY From The Last 14 Days Check below for free stories on PFE;MRK;BMY the last two weeks. |
|
|
| May 21, 2013 |
| 17:03 EDT |  | MRK | Merck announces $5B share repurchase
 Subscribe for More Information |
|
| 17:01 EDT | | MRK | Merck announces $5B accelerated share repurchase
Subscribe for More Information |
|
| 07:44 EDT | | MRK | Sachs Associates to host a forum
Subscribe for More Information |
|
| 07:34 EDT | | BMY | UBS to host a conference
Subscribe for More Information |
|
| 07:24 EDT | | BMY | Global Health Care to host a conference
Subscribe for More Information |
|
| 07:16 EDT | | PFE | Pfizer management to meet with Leerink
Subscribe for More Information |
|
| May 20, 2013 |
| 17:49 EDT |  | MRK | Merck sleep drug effective, dosages questioned, WSJ reports
Subscribe for More Information |
|
| 17:04 EDT | | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information |
|
| 10:03 EDT | | BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 07:32 EDT | | MRK | Society for Information Display / IHS to host a conference
Display Week 2013 is being held in Vancouver, British Columbia on May 19-24. |
| |
| 06:30 EDT |  | BMY | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT | | BMY | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 13:21 EDT |  | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT |  | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 08:55 EDT | | BMY, PFE, MRK | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 08:38 EDT | | BMY | Bristol-Myers shares likely to give back recent gains, says Leerink
Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. |
|
| 05:52 EDT | | BMY | Stocks with implied volatility movement; BMY SLV
Subscribe for More Information |
|
| May 15, 2013 |
| 11:28 EDT | | BMY | Options with increasing implied volatility: BMY AGNC EBIX IAU
Subscribe for More Information |
| |
|
|
|
|
